Flmodafinil

Wakefulness-promoting agent
Developed for treatment of a variety of different medical conditions. These include chronic fatigue syndrome, idiopathic hypersomnia, narcolepsy, attention deficit hyperactivity disorder (ADHD), and Alzheimer's disease.
The drug has been found to act as a selective atypical dopamine reuptake inhibitor.
Produces wakefulness-promoting effects in animals.
Unlike modafinil, flmodafinil does not induce cytochrome P450 enzymes.
Selective dopamine reuptake inhibitor (DRI).
Affinity (Ki) for the DAT is 4,090 nM.
At the serotonin transporter (SERT), its affinity (Ki) was 48,700 nM (12-fold lower than for the DAT).
Negligible affinity for the sigma σ1 receptor (Ki > 100,000 nM).
The drug has been found to block the dopamine transporter (DAT) by 83%, to a greater extent than methylphenidate without unfavorable concomitant adrenergic effects.
Atypical DRI similarly to modafinil.
Similarly to modafinil, (S)-(+)-flmodafinil and (R)-(–)-flmodafinil increase dopamine levels in the nucleus accumbens in animals. They have been found to increase dopamine levels by up to 150 to 200% of baseline at the highest assessed dose.
In contrast to modafinil, flmodafinil is not an inducer of the cytochrome P450 CYP3A4 or CYP3A5 enzymes.